VRCA — Verrica Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $45.22m
- $43.93m
- $7.57m
Annual income statement for Verrica Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 12 | 9.03 | 5.12 | 7.57 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 8.31 | 4.38 | 4.83 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 40.2 | 42.9 | 31.8 | 70.9 | 73.5 |
| Operating Profit | -40.2 | -30.9 | -22.7 | -65.8 | -65.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.7 | -35.1 | -24.5 | -67 | -76.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.71 | -1.3 | -0.675 | -1.42 | -1.47 |